The next significant price driver will be Carfilzomib's usage in earlier stages of MM. In this context, the ENDEAVOR and ASPIRE reults are very important. Does anybody know when we might have some results from these Phase III trials?
There have also been reports of very impressive response rates for newly diagnosed patients taking Kyprolis in combimation with Revlimid and other immunomodulatory agents. Are there any such studies undertaken by ONXX or are they being done by individual reserachers?